非阻塞性冠状动脉心肌梗死患者的抗血小板治疗
MINOCA患者30天内心血管死亡、再发心肌梗死及大出血风险均低于阻塞性冠心病患者;在MINOCA患者中,双倍剂量氯吡格雷组主要终点事件发生率高于标准剂量组(HR 3.57,95%CI 1.31-9.76),提示强化抗血小板治疗可能无额外获益甚至有害。
要点
- MINOCA患者30天全因死亡、心血管死亡、再发心肌梗死及大出血风险均低于阻塞性冠心病患者。
- MINOCA患者中双倍剂量氯吡格雷较标准剂量增加主要终点事件(HR 3.57,95%CI 1.31-9.76)。
- 阻塞性冠心病患者中双倍与标准剂量氯吡格雷主要终点无显著差异(HR 0.91,95%CI 0.80-1.03)。
核心结论
- MINOCA患者复发性心血管事件风险低于阻塞性冠心病心肌梗死患者。
- 与标准剂量氯吡格雷双联抗血小板治疗相比,强化剂量策略在MINOCA患者中无额外获益且可能有伤害信号。
- 需要进一步随机试验评估强效双联抗血小板治疗在MINOCA患者中的效果。
研究设计与样本
- 基于Clopidogrel and Aspirin Optimal Dose Usage to Reduce Recurrent Events-Seventh Organisation to Assess Strategies in Ischaemic Symptoms试验的分析,该试验将因急性冠脉综合征接受早期干预的患者随机分配至双倍剂量氯吡格雷组(第1天600mg,第2-7天150mg,之后75mg/天)或标准剂量组(第1天300mg,之后75mg/天)。
- 比较MINOCA与阻塞性冠心病患者结局,并评估标准剂量与双倍剂量氯吡格雷在两组中的关系。
- 主要终点为30天心血管死亡、心肌梗死或卒中。
主要发现
- MINOCA患者较阻塞性冠心病患者更年轻,非ST段抬高型心肌梗死比例更高,合并症更少。
- MINOCA患者全因死亡率0.6% vs 2.3%(p=0.005),心血管死亡率0.6% vs 2.2%(p=0.006),再发心肌梗死0.5% vs 2.3%(p=0.001),大出血0.6% vs 2.4%(p<0.0001)。
- MINOCA患者中双倍剂量氯吡格雷组主要终点发生率为2.1%,标准剂量组为0.6%(HR 3.57,95%CI 1.31-9.76)。
- 阻塞性冠心病患者中双倍剂量组主要终点发生率为4.3%,标准剂量组为4.7%(HR 0.91,95%CI 0.80-1.03;交互作用p=0.011)。
临床怎么用
- 对于MINOCA患者,标准剂量氯吡格雷为基础的双联抗血小板治疗可能优于强化剂量策略。
- 临床应认识到MINOCA患者总体预后优于阻塞性冠心病心肌梗死患者。
局限性
- 本研究为基于随机试验数据的分析,非专门针对MINOCA设计的随机试验。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Approximately 10% of patients with myocardial infarction (MI) have no obstructive coronary artery disease. The prognosis and role of intensified antiplatelet therapy in those patients were evaluated. METHODS: We analysed data from the Clopidogrel and Aspirin Optimal Dose Usage to Reduce Recurrent Events-Seventh Organisation to Assess Strategies in Ischaemic Symptoms trial randomising patients with ACS referred for early intervention to receive either double-dose (600 mg, day 1; 150 mg, days 2-7; then 75 mg/day) or standard-dose (300 mg, day 1; then 75 mg/day) clopidogrel. Outcomes in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA) versus those with obstructive coronary artery disease (CAD) and their relation to standard-dose versus double-dose clopidogrel were evaluated. The primary outcome was cardiovascular (CV) death, MI or stroke at 30 days. RESULTS: We included 23 783 patients with MI and 1599 (6.7%) with MINOCA. Patients with MINOCA were younger, presented more frequently with non-ST-segment elevation MI and had fewer comorbidities. All-cause mortality (0.6% vs 2.3%, p=0.005), CV mortality (0.6% vs 2.2%, p=0.006), repeat MI (0.5% vs 2.3%, p=0.001) and major bleeding (0.6% vs 2.4%, p<0.0001) were lower among patients with MINOCA than among those with obstructive CAD. Among patients with MINOCA, 2.1% of patients in the double-dose clopidogrel group and 0.6% in the standard-dose group experienced a primary outcome (HR 3.57, 95% CI 1.31 to 9.76), whereas in those with obstructive CAD, rates were 4.3% and 4.7%, respectively (HR 0.91, 95% CI 0.80 to 1.03; p value for interaction=0.011). CONCLUSIONS: Patients with MINOCA are at lower risk of recurrent CV events compared with patients with MI with obstructive CAD. Compared with a standard clopidogrel-based dual antiplatelet therapy (DAPT) regimen, an intensified dosing strategy appears to offer no additional benefit with a signal of possible harm. Further randomised trials evaluating the effects of potent DAPT in patients with MINOCA are warranted. TRIAL REGISTRATION NUMBER: NCT00335452.
引用
- Bossard M, Gao P, Boden W, et al. Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease. Heart. 2021. PMID: 33504513. doi:10.1136/heartjnl-2020-318045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。